Leerink sees Structure Therapeutics stock as “undervalued” (GPCR)
Alexey Krukovsky Leerink said Friday that it believes Structure Therapeutics (NASDAQ:GPCR) shares are “significantly undervalued” given the “extraordinary” total addressable market for oral GLP-1 diabetes drugs. The investment bank…
